Floatz logo

SITOCABNAGENE LOXIVELEUCEL EXPRESSED INDUCIBLE CASPASE-9 COMPRISING HUMAN CASPASE-9 FUSED TO A HUMAN FK506 BINDING PROTEIN VARIANT (FKBP-F36V)

B-Lymphoid Malignancies

M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

48 Active assets in the B-Lymphoid Malignancies cohort.

Asset / SponsorPhaseRating
Zanubrutinib
Curis, Inc.
Phase 2BB
Cyclophosphamide
University Hospital, Basel, Switzerland
Phase 2BB
PREDNISONE TABLETS
Curis, Inc.
Phase 2BB
Inno-206
Curis, Inc.
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Curis, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

SITOCABNAGENE LOXIVELEUCEL EXPRESSED INDUCIBLE CASPASE-9 COMPRISING HUMAN CASPASE-9 FUSED TO A HUMAN FK506 BINDING PROTEIN VARIANT (FKBP-F36V) is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →